Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Long-acting intramuscular injections of ELQ-331, an antimalarial agent.
Eur J Pharm Sci
July 2024
Pharmaceutical Sciences Group, Biosciences Division, SRI International, 333 Ravenswood Avenue, Menlo Park, CA, USA. Electronic address:
The overarching premise of this investigation is that injectable, long-acting antimalarial medication would encourage adherence to a dosage regimen for populations at risk of contracting the disease. To advance support for this goal, we have developed oil-based formulations of ELQ-331 (a prodrug of ELQ-300) that perform as long-acting, injectable chemoprophylactics with drug loading as high as 160 mg/ml of ELQ-331. In a pharmacokinetic study performed with rats, a single intramuscular injection of 12.
View Article and Find Full Text PDFA pharmacokinetic-pharmacodynamic model for chemoprotective agents against malaria.
CPT Pharmacometrics Syst Pharmacol
January 2023
Medicines for Malaria Venture, Geneva, Switzerland.
Chemoprophylactics are a vital tool in the fight against malaria. They can be used to protect populations at risk, such as children younger than the age of 5 in areas of seasonal malaria transmission or pregnant women. Currently approved chemoprophylactics all present challenges.
View Article and Find Full Text PDFNaturally-Occurring Bioactives in Oral Cancer: Preclinical and Clinical Studies, Bottlenecks and Future Directions.
Front Biosci (Schol Ed)
August 2022
Department of Life Sciences, National University of Kaohsiung, 811 Kaohsiung, Taiwan.
Oral cancer (OC) is the eighth most common cancer, particularly prevalent in developing countries. Current treatment includes a multidisciplinary approach, involving chemo, radio, and immunotherapy and surgery, which depends on cancer stage and location. As a result of the side effects of currently available drugs, there has been an increasing interest in the search for naturally-occurring bioactives for treating all types of cancer, including OC.
View Article and Find Full Text PDFHydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review.
Front Pharmacol
December 2020
Department of Medicine, All India Institute of Medical Sciences, New Delhi, India.
Article Synopsis
- Hydroxychloroquine has been considered as a potential drug for preventing COVID-19 due to its ability to inhibit SARS-CoV-2 in lab settings, but evidence from animal studies and clinical trials shows mixed results on its effectiveness.
- Issues such as inadequate drug concentrations and the effect of specific proteins in the respiratory system may contribute to its limited success in real-world applications.
- Ongoing clinical trials and safety concerns about higher doses highlight the need to explore alternative prevention strategies for high-risk populations.
Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni.
Acta Trop
December 2020
Department of Medical Parasitology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. Electronic address:
The control of schistosomiasis depends exclusively on praziquantel (PZQ) monotherapy with treatment failure due to minor activity against the juvenile stage, re-infection and emerging drug resistance. Improving the antischistosomal therapeutic/prophylactic profile of PZQ is a sensible option to save the clinical benefits of the drug if achieved effectively and safely via a single oral dose. Recently, we developed praziquantel-miltefosine lipid nanocapsules (PZQ 250 mg/kg-MFS 20 mg/kg LNCs) as a nanotechnology-enabled novel drug combination with significant multistage activity against Schistosoma mansoni (S.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!